SCM
BIO icon

Sandler Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Sandler Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-19,400
Closed -$5.93M – 142
2019
Q1 		$5.93M Buy
+19,400
New +$5.24M 0.46% 80
2018
Q2 		– Sell
-23,250
Closed -$5.81M – 114
2018
Q1 		$5.81M Buy
+23,250
New +$5.92M 0.71% 60
2017
Q3 		– Sell
-18,730
Closed -$4.24M – 114
2017
Q2 		$4.24M Buy
+18,730
New +$4.08M 0.46% 80

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Sandler Capital Management's BIO Position: Q2 2019 in Review

Sandler Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2019, closing a stake of 19,400 shares — an estimated $5.93M sold.

Sandler Capital Management first reported a position in BIO in Q2 2017 and held it in 3 quarters. The position peaked at $5.93M in Q1 2019. 330 funds tracked by Wall St. Rank hold BIO as of Q2 2019.

  • Sandler Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2019 after selling out during the quarter.
  • Sandler Capital Management sold 19,400 Bio-Rad Laboratories Class A shares in Q2 2019, an estimated $5.93M.
  • Sandler Capital Management first reported a position in Bio-Rad Laboratories Class A in Q2 2017 and held it in 3 quarters.
  • Sandler Capital Management's Bio-Rad Laboratories Class A position peaked at $5.93M in Q1 2019.
  • 330 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2019.

Based on Sandler Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.